Clinical trial NCT02363829: A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)
Official title: A Phase I Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Uterine Cervix Cancer
Keywords: clinical stages IIA, IIB, IIIA, IIIB, IVA
invasive carcinoma
uterine cervix
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2015-02-16
Enrollment: 6
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients 18 years of age and older with clinical stages IIA, IIB, IIIA, IIIB, IVA cervical carcinoma limited to the pelvis will receive twice daily oral nelfinavir (NFV) and weekly IV cisplatin in combination as radiosensitizers with daily whole pelvic external beam and intracavitary radiation brachytherapy.


Eligibility criteria: Inclusion Criteria:

* All patients with primary, previously untreated, histologically confirmed invasive carcinoma of the uterine cervix (any cell type). Clinical stages IIA, IIB, IIIA, IIIB, IVA. A representative H \& E stained slide showing documentation of the primary invasive cancer is required.
* Patients must have adequate bone marrow, renal and hepatic function:

Laboratory work must be performed within 30 days prior to start of study treatment.

ANC ≥ 1,500/μL; Platelet count ≥ 100,000/μL; Creatinine \< 2.0 mg/dL; Total Bilirubin ≤ 1.5 times normal; SGOT ≤ 3 times normal.

* Patients with a ECOG/GOG Performance Status of 0, 1, or 2.
* Patients with ureteral obstruction must be treated with stent or nephrostomy tube.
* Patients of childbearing potential must use an effective form of birth control."Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive measures should be used during therapy with VIRACEPT. "
* Confirmed seronegative HIV status within 3 months prior to start of study treatment.
* Patients must be at least 18 years of age.
* Patients must have signed an approved informed consent and authorization permitting release of personal health information.

Exclusion criteria

* Patients with Stage IA, IB or IVB disease.
* Patients who have known metastases to other organs outside the radiation field at the time of the original clinical and surgical staging.
* Patients who have received previous pelvic or abdominal radiation, cytotoxic chemotherapy, or previous therapy of any kind for this malignancy.
* Patients with septicemia or severe infection.
* Patients who have circumstances that will not permit completion of this study or the required follow-up.
* Patients who are pregnant at the time of diagnosis and do not wish pregnancy termination prior to initiation of treatment.
* Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of radiation fields.
* Patients with other concomitant malignancies (with the exception of non-melanoma skin cancer), who had (or have) any evidence of other cancer present within the last 5 years.
* Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).
* Patients with poorly controlled diabetes mellitus despite medication.
* Patients taking anti-arythmic agents such as amiodarone, quinidine, rifampin, ergot derivatives such as ergotamine, St John's Wort, HMG-CoA reductase inhibitors such as lovastatin, neuroleptic such as pimozide, sedatives such as midazolam and triazolam among other CYP3A4 and CYP2C19 substrates.
* Patients with Phenylketonuria

Primary outcomes:
measure: Number of Adverse Events
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Abramson Cancer Center of the University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: Abramson Cancer Center at Penn Medicine
name: Fiona Simpkins, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Abramson Cancer Center at Penn Medicine
name: Lilie Lin, MD
role: PRINCIPAL_INVESTIGATOR
References: